SE8800541A - - Google Patents

Info

Publication number
SE8800541A
SE8800541A SE8800541A SE8800541A SE8800541A SE 8800541 A SE8800541 A SE 8800541A SE 8800541 A SE8800541 A SE 8800541A SE 8800541 A SE8800541 A SE 8800541A SE 8800541 A SE8800541 A SE 8800541A
Authority
SE
Sweden
Prior art keywords
piperazinecarboxylic acid
disorders
img
tinnitus
epilepsy
Prior art date
Application number
SE8800541A
Other languages
English (en)
Other versions
SE8800541D0 (sv
SE467256B (sv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of SE8800541D0 publication Critical patent/SE8800541D0/xx
Publication of SE8800541A publication Critical patent/SE8800541A/xx
Publication of SE467256B publication Critical patent/SE467256B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650952Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8800541A 1987-02-18 1988-02-17 /r-(e)/-4-(3-fosfono-2-propenyl)-2-piperazinkarboxylsyra, foerfarande foer framstaellning av denna och en farmaceutisk komposition innehaallande foereningen SE467256B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878703749A GB8703749D0 (en) 1987-02-18 1987-02-18 Piperazinecarboxylic acid

Publications (3)

Publication Number Publication Date
SE8800541D0 SE8800541D0 (sv) 1988-02-17
SE8800541A true SE8800541A (nl) 1988-08-19
SE467256B SE467256B (sv) 1992-06-22

Family

ID=10612501

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8800541A SE467256B (sv) 1987-02-18 1988-02-17 /r-(e)/-4-(3-fosfono-2-propenyl)-2-piperazinkarboxylsyra, foerfarande foer framstaellning av denna och en farmaceutisk komposition innehaallande foereningen

Country Status (28)

Country Link
JP (1) JPH0723387B2 (nl)
KR (1) KR960015190B1 (nl)
AT (1) AT391320B (nl)
AU (1) AU613009B2 (nl)
BE (1) BE1002427A3 (nl)
CA (1) CA1327799C (nl)
CH (1) CH675125A5 (nl)
CY (1) CY1739A (nl)
DE (1) DE3804936C2 (nl)
DK (1) DK168441B1 (nl)
ES (2) ES2011319A6 (nl)
FI (1) FI86733C (nl)
FR (1) FR2610932B1 (nl)
GB (2) GB8703749D0 (nl)
GR (1) GR1002471B (nl)
HK (1) HK142093A (nl)
HU (2) HU199858B (nl)
IE (1) IE59098B1 (nl)
IL (1) IL85436A0 (nl)
IT (1) IT1219447B (nl)
LU (1) LU87129A1 (nl)
MY (1) MY103206A (nl)
NL (1) NL8800412A (nl)
NZ (1) NZ223529A (nl)
PH (1) PH25512A (nl)
PT (1) PT86776B (nl)
SE (1) SE467256B (nl)
ZA (1) ZA881146B (nl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU202111B (en) * 1988-03-11 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing (r)-(e)-4--(3-phosphono-2-propenyl)-2-piperazine-carboxylic acid as active component
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
EP0488959A3 (en) * 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
US5260286A (en) * 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
US6214604B1 (en) * 1995-05-08 2001-04-10 Lonza Ag Biotechnical production process of piperazine R-α-carboxylic acids and piperazine S-α-carboxylic acid amide
TR199902971T2 (xx) 1997-05-12 2001-03-21 Ortho-Mcneil Pharmaceutical, Inc. Selim prostat hiperplazisinin tedavisinde yararl� aril ikameli piperazinler.
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
JP2008124531A (ja) 2006-11-08 2008-05-29 Nec Electronics Corp 半導体装置およびオーディオプロセッサチップ
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids

Also Published As

Publication number Publication date
GB2201676A (en) 1988-09-07
DK168441B1 (da) 1994-03-28
IT8847631A0 (it) 1988-02-12
FR2610932B1 (fr) 1990-11-16
GR1002471B (el) 1996-11-15
HU199858B (en) 1990-03-28
HK142093A (en) 1994-01-07
IE880413L (en) 1988-08-18
DK79688A (da) 1988-08-19
LU87129A1 (fr) 1988-09-20
HU211269A9 (en) 1995-11-28
CH675125A5 (nl) 1990-08-31
PT86776B (pt) 1992-05-29
ATA36788A (de) 1990-03-15
GB8703749D0 (en) 1987-03-25
AT391320B (de) 1990-09-25
BE1002427A3 (fr) 1991-02-05
AU1175888A (en) 1988-08-25
GR880100084A (el) 1988-12-16
NZ223529A (en) 1991-02-26
SE8800541D0 (sv) 1988-02-17
GB8803438D0 (en) 1988-03-16
JPS63203691A (ja) 1988-08-23
AU613009B2 (en) 1991-07-25
KR960015190B1 (ko) 1996-11-01
KR880009944A (ko) 1988-10-06
GB2201676B (en) 1991-01-02
FI880744A0 (fi) 1988-02-17
DK79688D0 (da) 1988-02-16
IL85436A (nl) 1992-12-01
DE3804936A1 (de) 1988-09-01
IE59098B1 (en) 1994-01-12
MY103206A (en) 1993-05-29
PH25512A (en) 1991-07-24
NL8800412A (nl) 1988-09-16
FI86733B (fi) 1992-06-30
PT86776A (pt) 1988-03-01
IT1219447B (it) 1990-05-18
FR2610932A1 (fr) 1988-08-19
HUT49361A (en) 1989-09-28
ES2021904A6 (es) 1991-11-16
ZA881146B (en) 1989-10-25
CY1739A (en) 1995-10-20
DE3804936C2 (de) 1997-02-13
FI86733C (fi) 1992-10-12
CA1327799C (en) 1994-03-15
IL85436A0 (en) 1988-07-31
ES2011319A6 (es) 1990-01-01
JPH0723387B2 (ja) 1995-03-15
FI880744A (fi) 1988-08-19
SE467256B (sv) 1992-06-22

Similar Documents

Publication Publication Date Title
GB8817585D0 (en) Improvements in/relating to apparatus for use in treatment of spinal disorders
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
HU9300850D0 (en) Sulphonamido-pyridine-2-carboxylic acid amides as well as sulphonamido-carbonyl- ones, their n-oxides, method for producing them and pharmaceutical preparatives containing them
GB2207055B (en) Apparatus for use in the treatment of spinal disorders
HUP0105027A2 (hu) N-Heterociklusos vegyületek karbonsavszármazékai és karbonsav-izoszterei és alkalmazásuk
MY133393A (en) Phenyl xanthine derivatives
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
SE8800541A (nl)
GB9418912D0 (en) Pharmaceutically active compounds
BE902040A (fr) Alpha-aminoacides substitues, leur fabrication et compositions pharmaceutiques les contenant.
AU642428B2 (en) Method of treatment of CNS disorders and /or pain using gamma aminobutyric acid autoreceptor antagonists
WO2003066071A8 (en) Formulations comprising psychotropic drugs and selenium
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
EP0383171A3 (en) 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
DK317285A (da) Farmakologisk virksomme (pyrrol-1-yl)-phenyl-dihydropyridazinoner ogfremgangsmaade til fremstilling heraf
EP0273310A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
BG104368A (en) Novel polymorphic forms of cipamfylline
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
NZ224502A (en) Silyl alkylene amines and pharmaceutical use, methods for preparation and the treatment of non humans
FR2612774B1 (fr) Compositions cosmetiques et pharmaceutiques, utilisees pour traiter le processus de l'alopecie androgenogenetique, contenant de l'acide azelaique
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
IL124729A (en) Use of bismuth for the manufacture of compositions for the treatment and prevention of gastrointestinal disorders
Hori Applications of the Bi-Digital O-Ring Test for patients with TMD

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8800541-8

Format of ref document f/p: F

NUG Patent has lapsed